Fucosterol: A Comprehensive Reference Article
1. Identity and Chemical Characterization
1.1 Names and Classification
Fucosterol (24-ethylidene cholesterol) is a bioactive compound belonging to the sterol group that can be isolated from marine algae. Its systematic IUPAC name is (3β,24E)-stigmasta-5,24(28)-dien-3-ol, and it is also known by synonyms including (24E)-24-ethylidenecholesterol, isofucosterol (though this term is sometimes used for a related isomer), and Δ5-avenasterol in certain green-algal contexts. Fucosterol carries the molecular formula C₂₉H₄₈O and is catalogued under PubChem Compound ID (CID) 5281328. The compound has been obtained as a white powder based on EI-MS analysis.
Fucosterol is a phytosterol of marine algae, and as such it belongs to the broader class of triterpenoid-derived steroid alcohols. Phytosterols belong to the family of triterpenes, which include the four-ring steroid nucleus and the 3β-hydroxyl group. What distinguishes fucosterol within the phytosterol family is its characteristic Δ24(28) double bond in the side chain — the ethylidene group appended at carbon-24 — which is the structural feature reflected in its common name "24-ethylidene cholesterol." Phytosterols are structurally similar to cholesterol; however, most phytosterols contain 28 or 29 carbon atoms, with a side chain composed of 9 or 10 carbon atoms and one or two carbon-carbon double bonds. Typically, a 5,6-double bond appears at the steroid nucleus, and sometimes the alkyl side chain may also contain a double bond.
1.2 Physical Properties
Fucosterol is white needle-like crystals with a molecular weight of 412.7. Free phytosterols extracted from oils are insoluble in water, relatively insoluble in oil, and soluble in alcohols. Consistent with this, fucosterol is typically extracted using polar organic solvents. Its identification is routinely confirmed by gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance (NMR) spectroscopy. In the ¹H-NMR spectrum of fucosterol, two olefinic proton signals are detected, including δH 5.35 (1H, d, J = 5.5 Hz, H-6) and signals corresponding to the side-chain double bond.
1.3 Discovery and First Isolation
Fucosterol is a phytosterol abundant in brown algae, and was first identified in its pure form by Heilbron et al. (1934), who published an article highlighting its properties.
2. Natural Sources and Distribution
2.1 Primary Algal Sources
Fucosterol is a phytosterol of marine algae, with particular study for a variety of health benefits. Although seaweeds are known to be potential producers of phytosterols, not all species of seaweeds have evolved to do so. Only limited species, such as brown seaweed, have the ability to produce phytosterols such as fucosterol and saringosterol. Brown algae (class Phaeophyceae) are therefore the defining and richest biological source of fucosterol. Fucosterol is the major sterol in different brown algae genera including Sargassum and Undaria.
Key species documented in the literature as sources include:
- Sargassum fusiforme (hijiki) — widely studied in East Asia. Most of the studies on the bioactivity of S. fusiforme have focused on its antioxidant, anticancer and antitumor, anti-inflammatory, photoprotective, and neuroprotective properties, and the study of fucosterol in S. fusiforme has focused on antioxidant, anti-osteoarthritic, anti-inflammatory, anti-photoaging, antidiabetic, hepatoprotective, and algicidal effects.
- Ecklonia stolonifera (also referred to as Ecklonia cava subsp. stolonifera). Ecklonia cava subsp. stolonifera is the second most frequently reported macroalgal species studied for its fucosterol content. Ecklonia species have been known as potential sources of bioactive compounds, and fucosterol from Ecklonia stolonifera has been studied for its antidiabetic, anti-obesity, anti-neurological, and hepatoprotective effects.
- Eisenia bicyclis — used extensively in anti-inflammatory and antidiabetic studies. Fucosterol is derived from the brown alga Eisenia bicyclis and has various biological activities, including antioxidant, anticancer, and antidiabetic properties.
- Padina boryana — a brown alga widespread in Indo–Pacific waters. It has been applied in the isolation of fucosterol.
- Pelvetia siliquosa — used as a source for antidiabetic and antioxidant studies. The antioxidant effects of fucosterol were reported using Pelvetia siliquosa.
- Undaria pinnatifida (wakame). The anti-osteoporotic effect was evaluated using fucosterol derived from Undaria pinnatifida.
- Turbinaria conoides and Turbinaria ornata — tropical brown algae from which fucosterol has been isolated. Fucosterol has been obtained as the most abundant compound from brown algal species.
2.2 Concentration in Brown Algae
Fucosterol is present in brown algae in relatively large quantities: 0.9 mg/g to 13.4 mg/g dry weight. This variability is attributable to species-level differences, geographic and seasonal factors, and the portion of the alga analyzed. Fucosterol is typically the single dominant sterol in brown algae, whereas cholesterol is predominant in red seaweeds and different sterol profiles characterize green algae.
2.3 Biosynthesis
Phytosterol biosynthesis is a branch of sterol synthesis found in almost all plant species, and it can be distinguished from the sterol biosynthesis pathway of all eukaryotic kingdoms, such as animals and fungi. The paucity of investigation and the diversity of macroalgal species have obscured the identification of pathways responsible for phytosterol synthesis. Nevertheless, Calegario et al. postulated that seaweeds may use the traditional pathways of plants for isoprene unit synthesis. Like other phytosterols, fucosterol is built on a triterpenoid backbone; phytosterols cannot be synthesized by humans or animals, and are mainly obtained from plant-derived foods.
3. Traditional and Historical Use
3.1 East Asian Traditions
Fucosterol has not historically been isolated or recognized as a discrete compound in traditional medicine. Instead, it existed as a major constituent of seaweeds that were themselves deeply embedded in food and medicinal traditions of East Asia. The primary historical record concerns the seaweeds as whole materials rather than fucosterol per se.
The first use of Sargassum fusiforme as a traditional Chinese medicinal plant was recorded in the Shennong Bencao Jing, dated 200 AD. It was referred to as Haizao (seaweed), renowned for treating Yinglu (tumor-like induration), dysuria, and edema. Currently, it is commonly used in traditional cuisine as it is rich in dietary fiber and minerals such as calcium, iron, and magnesium. Owing to its health benefits, S. fusiforme remains popular in China, Korea, and Japan, as well as in the UK and North America.
3.2 Broader Seaweed Use in Traditional Medicine
Seaweeds — macroalgae or sea vegetables — are a diverse group of over 9,000 macroscopic and multicellular marine algae. With microalgae, seaweeds represent one of the most researched oceanic resources, turned to as treasure troves of bioactive compounds with ethnomedicinal, pharmaceutical, cosmeceutical, and dietetic end-uses for millennia.
Many species of brown seaweeds have been used in food products and also documented as being used in traditional medicine. Some Western herbal products containing Fucus vesiculosus are known to be used topically for the treatment of sore knees, healing wounds, and also as herbal teas for their laxative or weight control effects. F. vesiculosus has been reported for the treatment of the uterus and ovaries in the Caribbean islands.
It bears emphasizing that while the seaweeds containing fucosterol have ancient food and medicinal histories, the compound itself was not identified or isolated until 1934, and its specific biological contributions to traditional practices were not known to practitioners of those traditions. The traditional use documented above is therefore that of the whole plant/alga, not of isolated fucosterol.
4. Chemical Constituents and Active Compounds
4.1 Fucosterol as the Principal Sterol of Brown Algae
Sterols, also known as steroid alcohols, are essential lipid compounds found in the membranes of all eukaryotic cells and have multiple important functions such as controlling membrane permeability and fluidity. In photosynthetic organisms, phytosterols are plant-derived sterols that are structurally and functionally reminiscent of cholesterol in animals. Phytosterols have specific roles in cell proliferation, cell signaling, and modulating activities of membrane-bound enzymes.
Within brown algae, fucosterol is routinely co-isolated with a diverse array of other bioactive compounds — including fucoidans, phlorotannins, alginate, fucoxanthin, and other carotenoids — but fucosterol itself is the dominant sterol fraction. Sterols are an important group of steroids present in high quantities in seaweeds, and many health effects have been stated regarding the vital biological capacity of sterols, such as anti-inflammatory, anti-diabetic, antioxidant, and anti-cancer activity.
4.2 Structural Basis of Activity
The unique structural feature that distinguishes fucosterol from most terrestrial phytosterols is its (24E)-ethylidene double bond at C-24(28). This configuration places fucosterol within a small group of algal sterols distinct from β-sitosterol, campesterol, and stigmasterol — the dominant phytosterols of terrestrial plants. The 3β-hydroxyl group, shared with all phytosterols, is integral to membrane intercalation and to sterol–protein interaction. Plant sterols resemble cholesterol structurally in that they all have a steroid nucleus, a 3β-hydroxyl group, and a double bond between carbon atoms 5 and 6. The major differences are in side chain substitution and/or unsaturation.
5. Established Mechanisms of Action
5.1 Cholesterol Absorption Inhibition
Fucosterol shows a cholesterol-lowering effect by competing with cholesterol absorption, which is the same effect as plant sterols. Phytosterols in general are structurally similar enough to cholesterol to compete for the same intestinal micellar incorporation and transporter systems (such as NPC1L1), thereby reducing the fraction of dietary and biliary cholesterol that is absorbed. Despite well-documented LDL cholesterol-lowering effects from long-term consumption of phytosterols, typically in the range of about 5–10%, there is no conclusive evidence from long-term outcome trials that phytosterols themselves reduce the incidence of cardiovascular diseases.
5.2 Anti-Inflammatory Signaling
Fucosterol inhibits the expression of inducible nitric oxide synthase (iNOS), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) by downregulating transcription levels, and subsequently inhibits the production of nitric oxide, TNF-α, and IL-6. In addition, fucosterol attenuates LPS-induced DNA binding and NF-κB transcriptional activity. Fucosterol attenuates the phosphorylation of MKK3/6 and MK2 involved in the p38 MAPK pathway. These results indicate that the anti-inflammatory effect of fucosterol is related to the inhibition of NF-κB and p38 MAPK pathways.
In a model of acute liver injury, in ConA-induced acute liver injury, fucosterol decreased P38 MAPK phosphorylation and contributed to increased PPARγ transcriptional activity. Active PPARγ reduced the release of inflammatory factors that cause necrosis and apoptosis by inhibiting the NF-κB pathway. Additionally, Bcl-2, which is upregulated by PPARγ, can combine with Bax and Beclin-1 to reduce apoptosis and autophagy, respectively. Thus, fucosterol attenuates Concanavalin A-induced acute liver injury in mice via the P38 MAPK/PPARγ/NF-κB pathway.
5.3 Antidiabetic Enzyme Inhibition
One of the antidiabetic effects of fucosterol obtained from Eisenia bicyclis and Ecklonia cava subsp. stolonifera is characterized by inhibition of enzymes such as rat lens aldose reductase (RLAR), human recombinant aldose reductase (HRAR), α-glucosidase, and PTP1B. Docking simulations demonstrated negative binding energy for fucosterol (−8.2 kcal mol⁻¹ for RLAR and −8.5 kcal mol⁻¹ for HRAR), implying higher affinity and stronger binding competence for the active sites of these enzymes.
5.4 Neuroprotective Mechanisms
Fucosterol is an algae-derived unique phytosterol having several medicinal properties, including antioxidant, anti-inflammatory, anticholinesterase, and neuroprotective properties. Accumulated evidence suggests a therapeutic promise of fucosterol in neurodegeneration; however, the in-depth pharmacological mechanism of its neuroprotection is poorly understood. The PI3K/Akt signaling pathway downstream to the neurotrophin signaling pathway has been identified as one of the enriched pathways in fucosterol's pharmacological actions. Fucosterol has been reported to protect against Aβ1-42-induced cytotoxicity through activating TrkB-mediated ERK1/2 signaling in primary hippocampal neurons; this TrkB-dependent neuroprotective effect was reversed by a selective TrkB inhibitor. These in vitro cellular effects of fucosterol were further translated into in vivo effects, in which fucosterol ameliorates Aβ1-42-induced cognitive impairment in aging rats.
Fucosterol has the ability to reduce Aβ plaque formation, counter memory deficits, and increase acetylcholine levels in the brain.
5.5 Anti-adipogenic (Anti-obesity) Mechanism
Fucosterol treatment yielded a decrease in the expression of the adipocyte marker proteins peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer-binding protein α (C/EBPα) in a concentration-dependent manner. These results suggest that fucosterol inhibits expression of PPARγ and C/EBPα, resulting in a decrease of lipid accumulation in 3T3-L1 pre-adipocytes, indicating potential use as an anti-obesity agent.
5.6 Anticancer Mechanisms
Fucosterol has activity against ovarian cancer, inhibiting its proliferation and cell cycle by activating caspase-3, caspase-9, and cytochrome C due to mitochondrial dysfunction. Fucosterol also inhibits signal transduction pathways including PI3K and MAPK. Fucosterol significantly enhances the expression of Bax and cleaved caspase-3, which is related to a decreased expression of Bcl-2. The activation of the PI3K/Akt/mTOR pathway is very important in cancer tumorigenesis and chemotherapy resistance; fucosterol significantly inhibits the expression of key proteins in the PI3K/Akt/mTOR signaling pathway.
6. Scientific Evidence by Area of Use
6.1 Cardiovascular Health / Cholesterol Lowering
Evidence level: Preclinical (in vitro and animal); limited human data on phytosterols as a class, none specific to isolated fucosterol.
Fucosterol shows a cholesterol-lowering effect by competing with cholesterol absorption, the same effect as plant sterols. The existing human clinical evidence is for phytosterols broadly — not for fucosterol specifically. Despite well-documented LDL cholesterol-lowering effects from long-term consumption of phytosterols, typically in the range of about 5–10%, there is no conclusive evidence from long-term outcome trials that phytosterols themselves reduce the incidence of cardiovascular diseases, improve fasting blood sugar or glycated hemoglobin levels, or overall mortality rate. No clinical trials have been conducted with isolated fucosterol for cardiovascular endpoints. The FDA health claim on plant sterols applies to β-sitosterol, campesterol, and stigmasterol specifically. As early as 2001, the US FDA declared that plant sterols and plant sterol esters are safe foods and can be used in medicines, and in 2010, FDA authorized the fortification of foods using nonesterified or free phytosterols. The three phytosterols subject to the FDA health claim are β-sitosterol, campesterol, and stigmasterol. Fucosterol is not among those three.
6.2 Antidiabetic Effects
Evidence level: Preclinical (in vitro enzyme inhibition; in vivo animal models). No human clinical trials.
In vivo testing of fucosterol in streptozotocin-induced diabetic rats, isolated from the brown alga Pelvetia siliquosa, demonstrated that it is the main anti-diabetic principle. Fucosterol caused a significant decrease in serum glucose concentrations, and exhibited an inhibition of sorbitol accumulation in the lenses of rats. Fucosterol has shown to be an option in diabetes management, as it caused a decrease in concentrations of glucose in serum and inhibited the accumulation of sorbitol in lenses of diabetic rats. In another investigation, oral administration of fucosterol in epinephrine-induced diabetic rats leads to a decrease in blood glucose level and glycogen degradation.
At the enzyme level, one of the antidiabetic effects of fucosterol obtained from Eisenia bicyclis and Ecklonia cava subsp. stolonifera is characterized by inhibition of enzymes such as rat lens aldose reductase (RLAR), human recombinant aldose reductase (HRAR), α-glucosidase, and PTP1B. Inhibition of aldose reductase is clinically relevant because overactivity of this enzyme in hyperglycemic states leads to accumulation of sorbitol in peripheral tissues, contributing to diabetic neuropathy, retinopathy, and nephropathy. Inhibition of α-glucosidase slows postprandial glucose absorption, similar in principle to the pharmaceutical drug acarbose. All findings to date remain at the preclinical stage.
6.3 Anti-inflammatory and Immunomodulatory Effects
Evidence level: Preclinical (cell lines and animal models). No human clinical trials.
Fucosterol of marine macroalgae exhibited antidiabetic, anti-obesity, anti-osteoarthritic, immunomodulatory, anticancer, anti-inflammatory, anti-photoaging, hepatoprotective, anti-neurological, antioxidant, and antimicrobial activities. In macrophage models, fucosterol has been shown to suppress the NF-κB and p38 MAPK pathways. Serum TNF-α, IL-6, and IL-1β increased markedly after ConA treatment in mice, while fucosterol pretreatment inhibited their release, with the greatest effect at the maximum concentration.
In a study using macrophages exposed to particulate matter, fucosterol is a phytosterol that is abundant in marine brown algae and a renowned secondary metabolite, and its ability to protect macrophages against particulate matter (PM) has been studied with respect to inflammation. These effects are mediated through suppression of NF-κB and MAPK signaling, with additional involvement of the Nrf2/HO-1 antioxidant response pathway. All studies are preclinical.
6.4 Neuroprotection and Alzheimer's Disease
Evidence level: Preclinical (in vitro cell and in vivo rodent models); in silico pharmacological analysis. No human clinical trials.
According to the cholinergic hypothesis, memory impairment in Alzheimer's disease (AD) is associated with the deficit of cholinergic function in the brain. In addition, microglial activation plays an important role in AD by producing pro-inflammatory cytokines, nitric oxide, and prostaglandin E2. LPS and β-amyloid (Aβ) induce microglial activation leading to neuroinflammation and ultimately neuronal cell death.
Fucosterol demonstrated dual cholinesterase inhibitory properties and potential neuroprotective effects against LPS- and Aβ-induced neuroinflammation with its ability to regulate the production of pro-inflammatory mediators. These sterols have therapeutic implications, such as neurostimulatory effects, and have piqued the interest of the clinical community. The evidence base for fucosterol's neuroprotective effects remains limited to cell culture and rodent experiments. While the existing data is promising, rigorous, well-designed clinical trials are crucial to establish the safety and efficacy of fucosterol in humans. Additionally, further investigation into its bioavailability, pharmacokinetics, and optimal dosage for various applications will be essential.
6.5 Anticancer Activity
Evidence level: Preclinical (in vitro cancer cell lines and some in vivo xenograft animal models). No human clinical trials.
The anticancer effects of fucosterol have been studied in various types of cancer, including HT-29 colon cancer cells, breast cancer, promyelocytic leukemia, lung cancer, and cervical cancer.
Lung cancer: Fucosterol inhibits the growth of lung cancer cell lines, with the anticancer effects most pronounced against the A549 and SK-LU-1 cancer cells (IC₅₀, 15 µM). In contrast, the anticancer effects of fucosterol on non-cancerous lung cell lines were minimal. Further investigation revealed that the anticancer effects of fucosterol on the A549 and SK-LU-1 cells are due to the induction of apoptosis. Fucosterol also triggered G2/M cell cycle arrest in A549 and SK-LU-1 cells, which was associated with decreased expression of Cdc2, Cyclin A, and Cyclin B1, and upregulation of negative regulators of cell cycle progression (p21Cip1 and p27Kip1).
Cervical cancer: Fucosterol showed selective inhibitory activity on the human HeLa cervical cancer cell line with IC₅₀ of 40 μM. Fucosterol-induced HeLa cell apoptosis and changed the mitochondrial membrane potential mediated by reactive oxygen species.
Ovarian cancer: Commercially purchased fucosterol induced mitochondrial-mediated apoptosis, endoplasmic reticulum stress, and anti-angiogenic effects on human ovarian tumor cell lines (ES2 and OV90) with an IC₅₀ value of 62.4 μM (ES2) and 51.4 μM (OV90). Fucosterol inhibited cell proliferation and cell-cycle progression in ovarian cancer cells, and regulated the proliferation-related signaling pathways, the production of reactive oxygen species, mitochondrial function, endoplasmic reticulum stress, angiogenesis, and calcium homeostasis.
All anticancer findings are exclusively preclinical. No clinical trials in humans have been reported.
6.6 Hepatoprotection
Evidence level: Preclinical (mouse models). No human clinical trials.
In a murine model of concanavalin A-induced acute liver injury, fucosterol dissolved in 2% DMSO was orally administered daily at doses of 25, 50, and 100 mg/kg. The levels of hepatic necrosis, apoptosis, and autophagy associated with inflammatory cytokines were measured at 2, 8, and 24 hours. The study found a dose-dependent protective effect via the P38 MAPK/PPARγ/NF-κB pathway. Evidence from the literature supports fucosterol's hepatoprotective activity. All hepatoprotective findings are from animal models.
6.7 Anti-obesity and Anti-adipogenic Effects
Evidence level: Preclinical (in vitro adipocyte cell lines). No human clinical trials.
Fucosterol reduced lipid contents in a concentration-dependent manner without showing any cytotoxicity. Through its effects on adipogenic signaling pathways, fucosterol exhibits anti-obesity characteristics by suppressing adipogenesis in 3T3-L1 preadipocytes. The mechanism centers on downregulation of the master adipogenic transcription factors PPARγ and C/EBPα.
6.8 Antimicrobial Activity
Evidence level: Preclinical (in vitro only). No human clinical trials.
Crude extracts of brown algae species from which fucosterol was isolated exhibited a pronounced antimicrobial activity against the Gram-positive bacteria Bacillus cereus, Staphylococcus aureus, and Streptococcus pneumoniae. Antifungal properties have also been documented in laboratory settings. Whether these activities can be attributed specifically to the fucosterol fraction versus other co-extracted compounds requires further study.
6.9 Anti-photoaging and Skin Protection
Evidence level: Preclinical (cell models). No human clinical trials.
Fucosterol of marine macroalgae exhibited, among other activities, anti-photoaging properties. These have been investigated in keratinocyte and fibroblast cell models where fucosterol has been shown to attenuate UV-induced oxidative damage. Its antioxidant mechanism involves induction of the Nrf2/HO-1 pathway.
6.10 Osteoporosis / Bone Health
Evidence level: Preclinical. No human clinical trials.
The anti-osteoporotic effect was evaluated using fucosterol derived from Undaria pinnatifida. Cell-based studies have suggested fucosterol may support osteoblastic activity, but this area of research remains at an early stage.
7. Body Systems and Health Areas
Evidence from the literature supports fucosterol's various biological activities, including antioxidant, anti-inflammatory, anticancer, antidiabetic, cholesterol homeostasis, cholesterol-lowering, antihyperlipidemic, hepatoprotective, immunostimulatory, antimicrobial, antiobesity, and antidepressant potentials. These translate to associations with the following physiological systems:
- Cardiovascular system: Cholesterol absorption inhibition; potential antihyperlipidemic effects via competition with dietary cholesterol.
- Endocrine / Metabolic system: Antidiabetic via aldose reductase, α-glucosidase, and PTP1B inhibition; anti-adipogenic via PPARγ/C/EBPα suppression.
- Nervous system: Neuroprotective via TrkB/ERK signaling; anticholinesterase activity; modulation of neuroinflammation (microglial suppression of iNOS, NO, PGE2, pro-inflammatory cytokines).
- Hepatic system: Hepatoprotection via NF-κB and PPARγ pathways.
- Immune system: Immunomodulatory via NF-κB and MAPK pathway suppression; macrophage protection.
- Musculoskeletal system: Preliminary anti-osteoporotic and anti-osteoarthritic properties.
- Integumentary system: Anti-photoaging and antioxidant effects in skin cell models.
- Oncology: Antiproliferative across multiple cancer cell types via apoptosis, cell cycle arrest, and kinase pathway inhibition.
8. Dosage Forms and Reported Dosages
There is currently no established human clinical dosage for fucosterol. All dosage information in the literature derives from preclinical experiments.
- Animal (in vivo, oral) — hepatoprotection: Fucosterol was orally administered daily at doses of 25, 50, and 100 mg/kg in BALB/c mice.
- Cell culture (in vitro) — lung cancer: The anticancer effects were most profound against A549 and SK-LU-1 cancer cells at IC₅₀ of 15 µM.
- Cell culture (in vitro) — cervical cancer: Fucosterol showed selective inhibitory activity on the HeLa cervical cancer cell line with IC₅₀ of 40 μM.
- Cell culture (in vitro) — ovarian cancer: IC₅₀ values of 62.4 μM (ES2) and 51.4 μM (OV90) were reported for ovarian tumor cell lines.
Forms and preparations: Both traditional methods such as Soxhlet extraction and innovative technologies such as microwave-assisted extraction, pressurized solvent extraction, and supercritical fluid extraction have been applied for extraction of sterols from marine algae. Isolation has been conducted using silica open columns, while identification is assisted with gas chromatography-mass spectrometry (GC-MS) and NMR. Commercially, fucosterol is available as a purified powder for research purposes. It is also consumed as part of whole seaweed foods and powdered or encapsulated seaweed supplements, where it exists alongside other bioactive compounds.
9. Safety, Toxicology, and Potential Interactions
9.1 Overall Toxicological Profile
Published studies on the safety and toxicity of fucosterol from marine algae have focused on its effects on bacteria and fungi (21%), animal cell lines (14%), human cell lines (38%), and animals (26%). The safety and toxicity of fucosterol have been studied both in vitro and in vivo. No clinical study of fucosterol has been conducted to date. Fucosterol exhibited low toxicity in animal cell lines, human cell lines, and animals. However, studies on the safety and toxicity of fucosterol at the clinical stage, which are required before fucosterol is developed for the industry, are lacking.
9.2 Selectivity in Cancer Cell Lines
An important observation from anticancer studies concerns selectivity. The anticancer effects of fucosterol on non-cancerous lung cell lines were minimal. Further investigation confirmed that the anticancer effects of fucosterol on the A549 and SK-LU-1 cells are due to the induction of apoptosis, suggesting some degree of selectivity toward malignant over healthy cells, though this requires far more investigation before any clinical interpretation is warranted.
9.3 Anti-adipogenic Cytotoxicity Assessment
Fucosterol reduced lipid contents in a concentration-dependent manner without showing any cytotoxicity in 3T3-L1 preadipocyte experiments, supporting a degree of cellular safety at the concentrations tested in that model.
9.4 Absence of Regulatory Approval for Isolated Fucosterol
Fucosterol as an isolated compound has no approved therapeutic indication in any major regulatory jurisdiction. The US FDA authorized phytosterol fortification in foods using β-sitosterol, campesterol, and stigmasterol — with fucosterol not named under these provisions. Regulatory frameworks for fucosterol as a standalone supplement ingredient are absent.
9.5 Research Gaps and Caveats
Rigorous, well-designed clinical trials are crucial to establish the safety and efficacy of fucosterol in humans. Further investigation into its bioavailability, pharmacokinetics, and optimal dosage for various applications will be essential for its successful translation from the laboratory to the market. The development of standardized extraction and purification methods will also be critical to ensure the quality and consistency of fucosterol-containing products.
As a highly lipophilic compound, fucosterol is subject to the same bioavailability constraints as other phytosterols: poor aqueous solubility limits intestinal absorption, and formulation strategies (nanoemulsification, lipid-based delivery systems) are active areas of research. No data on drug–drug interactions with isolated fucosterol exist in the published literature, as no formal pharmacokinetic studies in humans have been completed.
10. Evidence Strength Summary
As of the time of this article's compilation, the entirety of the scientific evidence base for fucosterol's biomedical applications derives from in vitro cell experiments and in vivo animal models. No clinical study of fucosterol has been conducted to date; therefore, the investigation of the safety and toxicity of fucosterol at the clinical stage might be challenging. Phytosterols of marine algae, particularly fucosterol, have been investigated for a plethora of health benefits, including anti-diabetes, anti-obesity, anti-Alzheimer's, antiaging, anticancer, and hepatoprotection, among many others, which are attributed to their antioxidant, anti-inflammatory, immunomodulatory, and cholesterol-lowering properties, indicating their potentiality as therapeutic leads. The preclinical results are mechanistically plausible and internally consistent across multiple research groups, but translation to human therapeutics is not yet established. All areas of investigation should be considered preliminary.
References
Go back